RNS Number : 9000E
Omega Diagnostics Group PLC
11 November 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Investor presentation - Q&A Update
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that a recording of the online Company presentation, which was delivered live by Colin King, Chief Executive, and Kieron Harbinson, Group Finance Director on 28 October 2020 at 4:30pm GMT, surrounding the Company's previously announced Trading Update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.
Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group plc via the following link, which will take you to the recording of the presentation and the Q&A:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
No new price-sensitive information is disclosed as part of the presentation. Within the presentation the Company provides indicative guidance on timelines for product evaluations, product supply, potential timing for first commercial sales and targeted production volumes. These timelines are for guidance purposes only and there is no guarantee that these will be met. The Company expects to keep shareholders updated regularly on progress in achieving these future milestones.
Contacts:
Omega Diagnostics Group PLC
|
Tel: 01259 763 030
|
Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
|
www.omegadiagnostics.com
|
Kieron Harbinson, Group Finance Director
|
|
|
|
finnCap Ltd
|
Tel: 020 7220 0500
|
Geoff Nash/Edward Whiley (Corporate Finance)
|
|
Alice Lane (ECM)
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933 8780 or
omega@walbrookpr.com
|
Paul McManus
|
Mob: 07980 541 893
|
Lianne Cawthorne
|
Mob: 07584 391 303
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCDBLFFBFLEFBK
|